Fast-Tracking Biotech: Approvals, Deals, and Trials
Kilder
- BioSpace: Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher - BioSpace
- Pharmaphorum: Partner's Bizengri is first drug for rare, aggressive cancer - pharmaphorum
- Fiercepharma: Partner's bispecific Bizengri nabs FDA national priority nod in rare bile duct cancer - Fierce Pharma
- Bioworld: Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific - BioWorld News
- Bioworld: Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific - BioWorld News
- STAT: Five years after disaster, a rare disease community gets new chance at treatment - statnews.com
- STAT: Astellas treatment offers new hope to a devastated rare disease community - statnews.com
- Nature: A new treatment for preterm pre-eclampsia could benefit mother and child - Nature
- Fierce Biotech: Novo salvages happy ending for scrapped Parkinson’s cell therapy via deal with AI biotech - Fierce Biotech
- BioSpace: CRISPR-based Gene Editing Market Size to Hit USD 28.77 Billion by 2035 - BioSpace
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.